Tumor regression in long-term follow-up by administration of liposome encapsulated 5-FU. An animal experiment in WAF rats with CC-531 liver tumor
Pohlen, U.; Berger, G.; Jung, M.; Rezska, R.; Regenstein, J.; Buhr, H.J.
Langenbecks Archiv für Chirurgie. Suppl. Kongressband. Deutsche Gesellschaft für Chirurgie. Kongress 115(Suppl I): 625-629
1998
ISSN/ISBN: 0942-2854 PMID: 14518330 Document Number: 495478
Locoregional chemotherapy for inoperable colorectal liver metastases is not yet standard therapy. Only two studies thus far have reported prolonged survival. Better tolerance and an increased response rate speak in favor of regional chemotherapy. Liposome-encapsulated 5-FU is a new approach in regional chemotherapy. In this study i.v. and i.a. application of 5-FU-PEG liposomes were compared to a monosubstance with respect to tumor growth. Starch microspheres were added for flow decrease to examine the synergistic effect. The experiments were done in CC-531 liver tumor-bearing WAG rats. The results show a clear tumor reduction after 3 weeks of i.a. administration of 5-FU-PEG liposomes combined with a flow decrease by starch microspheres. There was a significant tumor reduction compared to all other i.a. groups. Strong tumor growth was observed in groups receiving i.v. application of 5-FU with liposomes or as a monosubstance. The results demonstrate tumor reduction after 3 weeks with locoregional chemotherapy by 5-FU-PEG liposomes combined with starch microspheres.